Inhibitory effect of cytotoxic stilbenes related to resveratrol on the expression of the VEGF, hTERT and c-Myc genes

European Journal of Medicinal Chemistry

Volumn 103, Issue , 2015, Pages 488-496

  Martí Centelles, Rosa ^a   Falomir, Eva ^a   Murga, Juan ^a   Carda, Miguel ^a   Marco, J Alberto ^b  

^a UNIVERSITAT JAUME I   (Spain)

^b UNIVERSITY OF VALENCIA   (Spain)

Author keywords

c Myc; Gene regulation; hTERT; Resveratrol; Stilbenes; Telomerase; VEGF

Indexed keywords

ANTINEOPLASTIC AGENT; MYC PROTEIN; RESVERATROL; STILBENE DERIVATIVE; TELOMERASE REVERSE TRANSCRIPTASE; VASCULOTROPIN; TELOMERASE; TERT PROTEIN, HUMAN; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; CROSS COUPLING REACTION; DRUG CYTOTOXICITY; DRUG STRUCTURE; ELECTROPHILICITY; ENZYME ACTIVATION; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE CONTROL; GENE EXPRESSION; HECK REACTION; HUMAN; HUMAN CELL; IC50; ONCOGENE C MYC; PROTEIN EXPRESSION; PROTEIN SECRETION; REVERSE TRANSCRIPTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; CHEMICAL STRUCTURE; CHEMISTRY; DOSE RESPONSE; DOWN REGULATION; DRUG EFFECTS; GENETICS; HEK293 CELL LINE; HT 29 CELL LINE; MCF 7 CELL LINE; STRUCTURE ACTIVITY RELATION; SYNTHESIS;

CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; HEK293 CELLS; HT29 CELLS; HUMANS; MCF-7 CELLS; MOLECULAR STRUCTURE; PROTO-ONCOGENE PROTEINS C-MYC; STILBENES; STRUCTURE-ACTIVITY RELATIONSHIP; TELOMERASE; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84942092974     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2015.09.014     Document Type: Article

References (57)

1. E.N. Frankel, A.L. Waterhouse, J.E. Kinsella, Inhibition of human LDL oxidation by resveratrol, Lancet 341 (1993) 1103-1104.
2. J. Marchal, F. Pifferi, F. Aujard, Resveratrol in mammals: effects on aging biomarkers, age-related diseases, and life span, Ann. N. Y. Acad. Sci. 1290 (2013) 67-73
3. R.S. Yao, X.Q. Lu, Q.X. Guan, L. Zheng, X. Lu, B.F. Ruan, Synthesis and biological evaluation of some novel resveratrol amide derivatives as potential anti-tumor agents, Eur. J. Med. Chem. 62 (2013) 222-231
4. M. Miliovsky, I. Svinyarov, Y. Mitrev, Y. Evstatieva, D. Nikolova, M. Chochkova, M.G. Bogdanov, A novel one-pot synthesis and preliminary biological activity evaluation of cis-restricted polyhydroxy stilbenes incorporating protocatechuic acid and cinnamic acid fragments, Eur. J. Med. Chem. 66 (2013) 185-192
5. A. Csiszar, Anti-inflammatory effects of resveratrol: possible role in prevention of age-related cardiovascular disease, Ann. N. Y. Acad. Sci. 1215 (2011) 117-122.
6. S. Quideau, D. Deffieux, L. Pouysegu, Resveratrol still has something to say about aging!, Angew. Chem. Int. Ed. 51 (2012) 6824-6826.
7. V. Krishnan, S.L. Zeichner, Host cell gene expression during human immunodeficiency virus type I latency and reactivation and effects of targeting genes that are differentially expressed in viral latency, J. Virol. 78 (2004) 9458-9473.
8. P.J. Elliott, S.M. Walpole, L. Morelli, P.D. Lambert, W. Lunsmann, C.H. Westphal, S. Lavu, Resveratrol/SRT501 Sirtuin SIRT1 activator treatment of type 2 diabetes, Drugs Future 34 (2009) 291-295.
9. C.R. Pace-Asciak, S. Hahn, E.P. Diamandis, G. Soleas, D.M. Goldberg, The red wine phenolics trans-resveratrol and quercetin block human plateletaggregation and eicosanoid synthesis e implications for protection against coronary heart-disease, Clin. Chim. Acta 235 (1995) 207-219.
10. J.A. Parker, M. Arango, S. Abderrahmane, E. Lambert, C. Tourette, H. Catoire, C. Neri, Resveratrol rescues mutant polyglutamine cytotoxicity in nematode and mammalian neurons, Nat. Genet. 37 (2005) 349-350.
11. M.S. Jang, E.N. Cai, G.O. Udeani, K.V. Slowing, C.F. Thomas, C.W.W. Beecher, H.H.S. Fong, N.R. Farnsworth, A.D. Kinghorn, R.G. Mehta, R.C. Moon, J.M. Pezzuto, Cancer chemopreventive activity of resveratrol, a natural product derived from grapes, Science 275 (1997) 218-220
12. T.P. Kondratyuk, E.-J. Park, L.E. Marler, S.Y. Ahn, Y. Yuan, Y.S. Choi, R. Yu, R.B. van Breemen, B. Sun, J. Hoshino, M. Cushman, K.C. Jermihov, A.D. Mesecar, C.J. Grubbs, J.M. Pezzuto, Resveratrol derivatives as promising chemopreventive agents with improved potency and selectivity, Mol. Nutr. Food Res. 55 (2011) 1249-1265.
13. D. Delmas, E. Solary, N. Latruffe, Resveratrol, a phytochemical inducer of multiple cell death pathways: apoptosis, autophagy and mitotic catastrophe, Curr. Med. Chem. 18 (2011) 1100-1121.
14. E. Brakenhielm, R.H. Cao, Y.H. Cao, Suppression of angiogenesis, tumor growth, and wound healing by resveratrol, a natural compound in red wine and grapes, FASEB J. 15 (2001) 1798-1800.
15. K. Igura, T. Ohta, Y. Kuroda, K. Kaji, Resveratrol and quercetin inhibit angiogenesis in vitro, Cancer Lett. 171 (2001) 11-16.
16. N. Ferrara, VEGF: an update on biological and therapeutic aspects, Curr. Opin. Biotechnol. 11 (2000) 617-624
17. P. Carmeliet, R.K. Jain, Molecular mechanisms and clinical applications of angiogenesis, Nature 473 (2011) 298-307.
18. S.M. Moghaddam, A. Amini, D.L. Morris, M.H. Pourgholami, Significance of vascular endothelial growth factor in growth and peritoneal dissemination of ovarian cancer, Cancer Metastasis Rev. 31 (2012) 143-162.
19. Z.P. Zhu, L. Witte, Inhibition of tumor growth and metastasis by targeting tumor-associated angiogenesis with antagonists to the receptors of vascular endothelial growth factor, Investig. New Drugs 17 (1999) 195-212
20. R.B. Caldwell, M. Bartoli, M.A. Behzadian, A.E.B. El-Remessy, M. Al-Shabrawey, D.H. Platt, G.I. Liou, R.W. Caldwell, Vascular endothelial growth factor and diabetic retinopathy: role of oxidative stress, Curr. Drug Targets 6 (2005) 511-524
21. A.F.C. Okines, A.R. Reynolds, D. Cunningham, Targeting angiogenesis in esophagogastric adenocarcinoma, Oncologist 16 (2011) 844-858.
22. For some relevant references, see, for example: (a) M. Potente, H. Gerhardt, P. Carmeliet, Basic and therapeutic aspects of angiogenesis, Cell 146 (2011) 873-887
23. G. Korpanty, E. Smyth, Anti-VEGF strategies e from antibodies to tyrosine kinase inhibitors: background and clinical development in human cancer, Curr. Pharm. Des. 18 (2012) 2680-2701
24. A.G. Linkous, E.M. Yazlovitskaya, Novel therapeutic approaches for targeting tumor angiogenesis, Anticancer Res. 32 (2012) 1-12.
25. Antiangiogenic therapies are not completely devoid of problems. See, for example: (a) A.R. Quesada, M.A. Medina, R. Muñoz-Chapuli, A.L.G. Ponce, Do not say ever never more: the ins and outs of antiangiogenic therapies, Curr. Pharm. Des. 16 (2010) 3932-3957
26. K. De Bock, M. Mazzone, P. Carmeliet, Antiangiogenic therapy, hypoxia, and metastasis: risky liaisons, or not? Nat. Rev. Clin. Oncol. 8 (2011) 393-404
27. L. Moserle, G. Jimenez-Valerio, O. Casanovas, Antiangiogenic therapies: going beyond their limits, Cancer Discov. 4 (2014) 31-41.
28. N.W. Kim, M.A. Piatyszek, K.R. Prowse, C.B. Harley, M.D. West, P.L.C. Ho, G.M. Coviello, W.E. Wright, S.L. Weinrich, J.W. Shay, Specific association of human telomerase activity with immortal cells and cancer, Science 266 (1994) 2011-2015
29. B.-S. Herbert, A.E. Pitts, S.I. Baker, S.E. Hamilton, W.E. Wright, J.W. Shay, D.R. Corey, Inhibition of human telomerase in immortal human cells leads to progressive telomere shortening and cell death, Proc. Natl. Acad. Sci. 96 (1999) 14276-14281.
30. J.W. Shay, W.E. Wright, Role of telomeres and telomerase in cancer, Semin. Cancer Biol. 21 (2011) 349-353
31. V.A. Zakian, Telomeres: the beginnings and ends of eukaryotic chromosomes, Exp. Cell Res. 318 (2012) 1456-1460.
32. K.A. Olaussen, K. Dubrana, J. Domont, J.-P. Spano, L. Sabatier, J.-C. Soria, Telomeres and telomerase as targets for anticancer drug development, Crit. Rev. Oncol. Hematol. 57 (2006) 191-214
33. D.R. Corey, Telomeres and telomerase: from discovery to clinical trials, Chem. Biol. 16 (2009) 1219-1223
34. C.M. Buseman, W.E. Wright, J.W. Shay, Is telomerase a viable target in cancer? Mut. Res. 730 (2012) 90-97.
35. G. Lanzilli, M.P. Fuggetta, M. Tricarico, A. Cottarelli, A. Serafino, R. Falchetti, G. Ravagnan, M. Turriziani, R. Adamo, O. Franzese, E. Bonmassar, Resveratrol down-regulates the growth and telomerase activity of breast cancer cells in vitro, Int. J. Oncol. 28 (2006) 641-648.
36. See, for example: C.-T. Chen, M.-C. Hung, Beyond anti-VEGF: dual-targeting antiangiogenic and antiproliferative therapy Am. J. Transl. Res. 5 (2013) 393-403.
37. R. Martí-Centelles, R. Cejudo-Marín, E. Falomir, J. Murga, M. Carda, J.A. Marco, Inhibition of VEGF expression in cancer cells and endothelial cell differentiation by synthetic stilbene derivatives, Bioorg. Med. Chem. 21 (2013) 3010-3015.
38. R. Heck, Palladium-catalyzed reactions of organic halides with olefins, Acc. Chem. Res. 12 (1979) 146-151
39. I.P. Beletskaya, A.V. Cheprakov, The Heck reaction as a sharpening stone of palladium catalysis, Chem. Rev. 100 (2000) 3009-3066
40. A.F. Schmidt, A. Al Halaiqa, V.V. Smirnov, Interplays between reactions within and without the catalytic cycle of the Heck reaction as a clue to the optimization of the synthetic protocol, Synlett (2006) 2861-2878.
41. N. Sharma, D. Mohanakrishnan, A. Shard, A. Sharma, Saima, A.K. Sinha, D. Sahal, Stilbene-chalcone hybrids: design, synthesis, and evaluation as a new class of antimalarial scaffolds that trigger cell death through stage specific apoptosis, J. Med. Chem. 55 (2012) 297-311.
42. V.P. Mehta, E.V. Van der Eycken, Microwave-assisted CeC bond forming crosscoupling reactions: an overview, Chem. Soc. Rev. 40 (2011) 4925-4936.
43. S.-H. Huang, J.-R. Chen, F.-Y. Tsai, Palladium(II)/cationic 2,20-bipyridyl system as a highly efficient and reusable catalyst for the Mizoroki-Heck reaction in water, Molecules 15 (2010) 315-330.
44. K.S. Keshavamurthy, Y.D. Vankar, D.N. Dhar, Preparation of acid anhydrides, amides, and esters using chlorosulfonyl isocyanate as a dehydrating agent, Synthesis (1982) 506-508.
45. N. Arden, M.J. Betenbaugh, Life and death in mammalian cell culture: strategies for apoptosis inhibition, Trends Biotechnol. 22 (2004) 174-180.
46. B.K. Van Weemen, A.H.W.M. Schuurs, Immunoassay using antigen-enzyme conjugate, FEBS Lett. 15 (1971) 232-236
47. E. Engvall, P. Perlmann, Enzyme-linked immunosorbent assay, ELISA. 3. quantitation of specific antibodies by enzyme-labeled anti-immunoglobulin in antigen-coated tubes, J. Immunol. 109 (1972) 129-135
48. A.J. O'Beirne, H.R. Cooper, Heterogeneous enzyme immunoassay, J. Hystochem. Cytochem 27 (1979) 1148-1162.
49. M. Nakamura, Y. Abe, T. Tokunaga, Pathological significance of vascular endothelial growth factor A isoform expression in human cancer, Pathol. Int. 52 (2002) 331-339.
50. S.A. Bustin, V. Benes, J.A. Garson, J. Hellemans, J. Huggett, M. Kubista, R. Mueller, T. Nolan, M.W. Pfaffl, G.L. Shipley, J. Vandesompele, C.T. Wittwer, The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments, Clin. Chem. 55 (2009) 611-622.
51. A. Albihn, J.I. Johnsen, M.A. Henriksson, MYC in oncogenesis and as a target for cancer therapies Adv. Cancer Res. 107 (2010) 163-224.
52. J. Dwyer, H. Li, D. Xu, J.-P. Liu, Transcriptional regulation of telomerase activity e roles of the the Ets transcription factor family, Ann. N. Y. Acad. Sci. 1114 (2007) 36-47
53. S. Kyo, M. Takakura, T. Fujiwara, M. Inoue, Understanding and exploiting hTERT promoter regulation for diagnosis and treatment of human cancers, Cancer Sci. 99 (2008) 1528-1538
54. M. Daniel, G.W. Peek, T.O. Tollefsbol, Regulation of the human catalytic subunit of telomerase (hTERT), Gene 498 (2012) 135-146.
55. J.J. Heynekamp, W.M. Weber, L.A. Hunsaker, A.M. Gonzales, R.A. Orlando, L.M. Deck, D.L.V. Jagt, Substituted trans-stilbenes, including analogues of the natural product resveratrol, inhibit the human tumor necrosis factor alphainduced activation of transcription factor nuclear factor KappaB, J. Med. Chem. 49 (2006) 7182-7189.
56. L.A. Stivala, M. Savio, F. Carafoli, P. Perucca, L. Bianchi, G. Maga, L. Forti, U.M. Pagnoni, A. Albini, E. Prosperi, V. Vannini, Specific structural determinants are responsible for the antioxidant activity and the cell cycle effects of resveratrol, J. Biol. Chem. 276 (2001) 22586-22594.
57. S. Rodríguez-Nieto, M.A. Medina, A.R. Quesada, A re-evaluation of fumagillin selectivity towards endothelial cells, Anticancer Res. 21 (2001) 3457-3460.